Last reviewed · How we verify
Immulina TM
Immulina TM is an immunotherapeutic agent designed to enhance immune system function and modulate immune responses.
At a glance
| Generic name | Immulina TM |
|---|---|
| Also known as | Spirulina |
| Sponsor | University of Mississippi Medical Center |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
While specific mechanistic details are limited in public literature, Immulina TM appears to function as an immunomodulatory therapy developed at the University of Mississippi Medical Center. The drug is currently in Phase 3 clinical development, suggesting it has demonstrated preliminary efficacy and safety in earlier trial phases.
Approved indications
Common side effects
Key clinical trials
- Spirulina Oral Supplement for Enhancing Host Resilience to Virus Infection (PHASE3)
- Effects of Immulina TM Supplements With PASC Patients (PHASE3)
- Identification of Surrogate Blood and/or Urine Biomarker for Immulina TM (Trademark) in Normal Humans (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Immulina TM CI brief — competitive landscape report
- Immulina TM updates RSS · CI watch RSS
- University of Mississippi Medical Center portfolio CI